Gadobutrol Enhanced MRA of the Supra-aortic Vessels

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 479 participants.

Also called NCT01344447

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 479 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01344447
  • EudraCT 2010-023001-36
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, China, Czechia, France, Germany, Italy, Poland, South Korea, Sweden, Switzerland, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01344447. Allocation not applicable; no masking; primary purpose diagnostic. Start 2011-05-12 (actual); primary completion 2014-05-28 (actual). Results posted on 2015-08-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Acronym
GEMSAV
Condition
Carotid Stenosis
Intervention (Drug)
Gadobutrol (Gadovist, BAY86-4875)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01344447
Content hash
aab93a5679c2f11f6e43a002d81fc599c5192795b0e53727d014ea6b03467fb7